Cytomed TherapeuticsGDTC
13F holders, Q2 2026 (June 30)3holders
1new positions
1sold out
$1.03avg. 13F price*
At the end of Q2 2026, 3 institutions reported holding Cytomed Therapeutics Ltd. (GDTC) in their 13F filings, unchanged from Q1 2026. 1 opened new positions and 1 sold out. The largest holders were Axiom Investment Management LLC ($7K), UBS Group AG ($5K) and Osaic Holdings, Inc. ($21).
- Company
- Cytomed Therapeutics Ltd.
- CUSIP
- Y1R80M106
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2026 → Q2 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $7K |
| Exits | 1 | $10K |
All 13F filers, Q1 2026 → Q2 2026: 7,032 shares bought and 11,487 shares sold, net −4,455 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 3 holders
| Axiom Investment Management LLC | 0.00% | New | 7,032 | $7K |
| UBS Group AG | 0.00% | Reduce -21.9% | 4,831 | $5K |
| Osaic Holdings, Inc. | 0.00% | No change | 21 | $21 |
"% of holder's portfolio" is GDTC's weight in each manager's 13F, not the share of Cytomed Therapeutics Ltd. the manager owns.